Sarepta Therapeutics Past Earnings Performance
Past criteria checks 0/6
Sarepta Therapeutics's earnings have been declining at an average annual rate of -8%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 27.1% per year.
Key information
-8.0%
Earnings growth rate
-2.2%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 27.1% |
Return on equity | -62.4% |
Net Margin | -43.1% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues
Dec 20Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder
Jul 29Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
May 09Sarepta: The DMD Leader
Apr 26Sarepta: Still A Solid Long-Term Bet On Sales And Next Generation Treatments
Feb 09Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Feb 07A Look At The Intrinsic Value Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Dec 06Sarepta: Revenue Keeps Rising While We Wait For Functional Data
Nov 01Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?
Nov 01Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Jul 19Sarepta Therapeutics: Faultlines May Run Deeper Than Assumed
Jun 02Most Shareholders Will Probably Agree With Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Compensation
May 27Revenue & Expenses BreakdownBeta
How Sarepta Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,243 | -536 | 482 | 0 |
30 Sep 23 | 1,105 | -691 | 471 | 0 |
30 Jun 23 | 1,003 | -908 | 455 | 0 |
31 Mar 23 | 976 | -1,115 | 490 | 0 |
31 Dec 22 | 933 | -703 | 451 | 0 |
30 Sep 22 | 876 | -716 | 409 | 0 |
30 Jun 22 | 835 | -507 | 365 | 0 |
31 Mar 22 | 766 | -357 | 283 | 0 |
31 Dec 21 | 702 | -419 | 283 | 0 |
30 Sep 21 | 646 | -486 | 291 | 0 |
30 Jun 21 | 600 | -634 | 305 | 0 |
31 Mar 21 | 573 | -704 | 306 | 0 |
31 Dec 20 | 540 | -554 | 318 | 0 |
30 Sep 20 | 495 | -601 | 313 | 0 |
30 Jun 20 | 450 | -530 | 313 | 0 |
31 Mar 20 | 407 | -656 | 307 | 0 |
31 Dec 19 | 381 | -715 | 285 | 0 |
30 Sep 19 | 365 | -620 | 268 | 0 |
30 Jun 19 | 345 | -570 | 245 | 0 |
31 Mar 19 | 323 | -403 | 227 | 0 |
31 Dec 18 | 301 | -362 | 208 | 0 |
30 Sep 18 | 274 | -245 | 178 | 0 |
30 Jun 18 | 241 | -216 | 153 | 0 |
31 Mar 18 | 203 | -170 | 133 | 0 |
31 Dec 17 | 155 | -51 | 123 | 166 |
30 Sep 17 | 103 | -115 | 105 | 0 |
30 Jun 17 | 57 | -124 | 99 | 0 |
31 Mar 17 | 22 | -123 | 87 | 0 |
31 Dec 16 | 5 | -267 | 81 | 0 |
30 Sep 16 | 1 | -243 | 85 | 0 |
30 Jun 16 | 1 | -239 | 78 | 0 |
31 Mar 16 | 1 | -218 | 73 | 0 |
31 Dec 15 | 1 | -220 | 66 | 0 |
30 Sep 15 | 0 | -200 | 55 | 0 |
30 Jun 15 | 1 | -177 | 53 | 0 |
31 Mar 15 | 4 | -169 | 52 | 0 |
31 Dec 14 | 10 | -136 | 49 | 0 |
30 Sep 14 | 12 | -100 | 45 | 0 |
30 Jun 14 | 15 | -113 | 41 | 0 |
31 Mar 14 | 16 | -98 | 36 | 0 |
31 Dec 13 | 14 | -112 | 32 | 0 |
30 Sep 13 | 19 | -165 | 26 | 0 |
30 Jun 13 | 22 | -173 | 22 | 0 |
Quality Earnings: SRPT is currently unprofitable.
Growing Profit Margin: SRPT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SRPT is unprofitable, and losses have increased over the past 5 years at a rate of 8% per year.
Accelerating Growth: Unable to compare SRPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SRPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: SRPT has a negative Return on Equity (-62.37%), as it is currently unprofitable.